Seek Returns

VTRS vs. ZTS: Viatris vs. Zoetis Stock Comparison

How do Viatris (VTRS) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Viatris (VTRS) and Zoetis (ZTS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Viatris (VTRS) and Zoetis (ZTS)
Profile ItemVTRSZTS
NameViatris Inc.Zoetis Inc. Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization22.83 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateMarch 17, 1980February 1, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

VTRS
ZTS
GSPC
Loading price history…
Viatris (VTRS) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Viatris (VTRS) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Viatris (VTRS) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Viatris (VTRS) and Zoetis (ZTS)
MetricVTRSZTS
Total Return (1Y)108.98%-30.10%
Total Return (3Y, Annualized)36.75%-20.42%
Total Return (5Y, Annualized)11.59%-16.87%

Risk Profile

Drawdown History

VTRS
ZTS
GSPC
Loading price history…
Viatris (VTRS) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Viatris (VTRS) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Viatris (VTRS) and Zoetis (ZTS)
MetricVTRSZTS
Volatility (1Y, Annualized)32.53%38.23%
Beta (5Y)0.860.66
Max Drawdown (5Y)-45.69%-70.45%
Avg. Volume (3M)8.87M4.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
VTRS and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Viatris (VTRS) and Zoetis (ZTS)
MetricVTRSZTS
Sharpe Ratio (1Y)3.22-0.90
Sortino Ratio (1Y)5.63-1.10

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Zoetis (ZTS) reports 57.63%, ranking against industry peers normally.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Zoetis (ZTS) reports 26.41%, ranking against industry peers normally.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Zoetis (ZTS) at 38.19% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Viatris (VTRS) and Zoetis (ZTS)
MetricVTRSZTS
ROE (TTM)-4.21%57.63%
ROA (TTM)2.91%14.87%
Net Margin (TTM)-4.13%26.41%
Operating Margin (TTM)13.85%38.19%
Gross Margin (TTM)41.13%71.65%

Growth

Revenue Growth

Zoetis (ZTS) at 2.28% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Zoetis (ZTS) reports EPS growth of 10.05%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Viatris (VTRS) and Zoetis (ZTS)
MetricVTRSZTS
Revenue Growth (YoY)-2.98%2.28%
Revenue Growth (3Y CAGR)-4.20%5.42%
EPS Growth (YoY)--10.05%
EPS Growth (3Y CAGR)--10.27%

Financial Strength

Current Ratio (MRQ)

Both Viatris (VTRS) at 1.55 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but ZTS is more stretched: Viatris (VTRS) at 0.99 sits in the higher-leverage quartile and Zoetis (ZTS) at 2.80 is above its industry benchmark range.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Viatris (VTRS) and Zoetis (ZTS)
MetricVTRSZTS
Current Ratio (MRQ)1.552.35
Debt / Equity (MRQ)0.992.80
Net Debt / EBITDA2.641.92

Dividends

Dividend Yield (TTM)

Both Viatris (VTRS) at 2.53% and Zoetis (ZTS) at 2.55% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Zoetis (ZTS) reports 35.24%, ranking against industry peers normally.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Viatris (VTRS) and Zoetis (ZTS)
MetricVTRSZTS
Dividend Yield (TTM)2.53%2.55%
Dividend Payout Ratio (TTM)960.00%35.24%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Zoetis (ZTS) trades at 13.50 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): VTRS does not report P/E ratio, so it has no value marker; ZTS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Zoetis (ZTS) at 3.40 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 looks cheap against book in the lower P/B ratio quartile, while Zoetis (ZTS) at 9.80 carries a premium in the upper quartile — a clear price-to-book gap.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Viatris (VTRS) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Viatris (VTRS) and Zoetis (ZTS)
MetricVTRSZTS
P/E Ratio (TTM)--13.50
P/S Ratio (TTM)1.553.40
P/B Ratio (MRQ)1.679.80
Free Cash Flow Yield (TTM)13.84%6.36%